top of page

Advanced collagen-based biomaterials for the life sciences

THE COMPANY

We are an innovative biotech company that is focused on developing high-end collagen-based biomaterials to help support, heal or rebuild tissues in the human body.

From its founding in 2017 by a diverse group of biotech scientists and entrepreneurs, Promed Bioscience has rapidly evolved into a leading innovator in the production and distribution of customized collagen formulations, including our flagship product, medical-grade atelocollagen.

Today, we stand at the forefront of the tissue regeneration market, delivering tailor-made collagen solutions that meet the strict regulatory standards and specifications of our diverse global client list.

1.JPG

VALUE PROPOSITION

  • Highly experienced R&D team with strong technical and scientific backgrounds and expertise.

  • Collagen biomaterials extracted using proprietary methods that preserve the mechanical and biological properties of the native protein as in the human body. ​

  • Offering complementary R&D services through access and partnerships with academic, research and clinical institutions.

  • Focused on long term partnerships and working closely with clients for the co-development of innovative customized formulations.

  • Controlled animal tissue sources & direct access to the raw material under strict EU regulations.

  • Adherence to industry-leading quality benchmarks (ISO 13485 and GMP compliance) to facilitate regulatory approval for use in medical implants.

KEY MARKET MILESTONES

Promed distributes its high-end products to clients worldwide, with particular emphasis on the fast-growing tissue engineering and regenerative medicine markets. The company maintains strategic partnerships with companies in the US to provide medical-grade collagen for 3D bioprinting of organs and tissues and has signed supplier agreements with European firms developing collagen-based dermaceuticals and wound healing formulations.

Promed has recently entered the South Korean market and has secured several multi-year contracts, worth over €32 million in total, to provide atelocollagen-based biomaterials to Korean medical devices manufacturers.

INVESTMENT CONSIDERATIONS

  • Over €1M in investment funds raised so far with the total equity held by non-founders / investors at 35%.

  • New Korean contracts will require major expansion of production capacity and a significant investment in new infrastructure.

  • New investment funding required: €500K, of which at least €300K will be spent on new equipment such as specialized mixing systems, high-capacity centrifuges, freeze-dryers and filtration systems.

  • Promed Bioscience is a certified innovative SME-->tax incentives for prospective investors (tax-deductible investment).

2.JPG
3.jpg

THE WAY FORWARD

  • Rapid expansion of regenerative medicine and medical devices markets will be the main drivers of growth going forward for high-end medical collagen.

  • Significant sales traction expected with the signing of several multi-year contracts with South Korean medical devices manufacturers.

  • YoY revenue growth of >100% expected in the next 5 years based on already secured contracts.

  • Plans for a Cyprus-based joint venture with US medical devices manufacturer presents another major opportunity for growth.

4.jpg
Untitled design (13).png
bottom of page